Cadre Holdings, Inc.
CDRE NYSE Orthopedic, Prosthetic & Surgical Appliances & Supplies Financials FY2020–FY2025
Last close · Oct 23, 2026
$29.99
1.8%What Cadre Holdings, Inc. does
No business description yet.
- Legal name
- Cadre Holdings, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Accession · CIK
- 0001104659-26-025862
0001860543
Revenue and margins
Cadre Holdings, Inc. had $610M of revenue in fiscal 2025, up 7.5% on the year before.
Net income and earnings per share
From fiscal 2020 to 2025, diluted EPS grew −6.1% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $56.8M in fiscal 2025, 9.3% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Cadre Holdings, Inc. returned $15.4M to shareholders in fiscal 2025, 27% of free cash flow. The diluted share count rose 7.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably Cadre Holdings, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $33.9M | $45.3M | $87.7M | $125M | $123M |
| Debt incl. finance leases | $173M | $152M | $142M | $223M | $326M |
| Net debt / EBITDA | 2.1x | 3.3x | 0.8x | 1.2x | 2.4x |
| Debt / equity | 2.0x | 0.9x | 0.7x | 0.7x | 1.0x |
| Interest coverage | 3.1x | 2.7x | 12.5x | 8.5x | — |
| Current ratio | 2.1x | 2.5x | 2.6x | 3.5x | 3.5x |
| Quick ratio | 1.3x | 1.6x | 1.7x | 2.6x | 2.5x |
| Total assets | $312M | $392M | $431M | $653M | $770M |
| Total liabilities | $223M | $226M | $234M | $341M | $452M |
| Shareholders' equity | $88.6M | $166M | $197M | $312M | $318M |
| Net debt (− = net cash) | $139M | $107M | $54.6M | $98.3M | $203M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Return on assets rose | — | ✕ | ✕ | ✓ | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✕ | ✓ |
| Debt fell relative to assets | — | ✓ | ✓ | ✓ | ✕ | ✕ |
| Current ratio rose | — | ✓ | ✓ | ✓ | ✓ | ✓ |
| Share count didn't rise | — | ✕ | ✕ | ✕ | ✕ | ✕ |
| Gross margin rose | — | ✓ | ✕ | ✓ | ✕ | ✓ |
| Revenue rose relative to assets | — | ✕ | ✕ | ✕ | ✕ | ✕ |
| F-score | — / 3 | 6 / 9 | 5 / 9 | 7 / 9 | 3 / 9 | 6 / 9 |
| Accruals ratio | −2.5% | −9.2% | −11.5% | −8.4% | 0.8% | −2.8% |
| Altman Z'' | 2.06 | 2.94 | 2.68 | 3.94 | 4.02 | 3.70 |
6 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $405M | $427M | $458M | $483M | $568M | $610M |
| Gross profit | $153M | $171M | $176M | $201M | $233M | $260M |
| Research and development | $5.6M | $6.5M | $7.1M | $7.0M | $8.4M | $11.4M |
| Operating income | $49.8M | $51.7M | $16.7M | $56.5M | $66.8M | $67.4M |
| Interest expense | $24.4M | $16.4M | $6.2M | $4.5M | $7.8M | — |
| Pretax income | $27.9M | $19.2M | $9.4M | $52.9M | $54.2M | $62.3M |
| Income tax | −$10.6M | $6.5M | $3.6M | $14.3M | $18.1M | $18.2M |
| Net income | $38.5M | $12.7M | $5.8M | $38.6M | $36.1M | $44.1M |
| Net income to common | $38.5M | $12.7M | $5.8M | $38.6M | $36.1M | $44.1M |
| Diluted EPS | $1.40 | $0.44 | $0.16 | $1.02 | $0.90 | $1.02 |
| Diluted shares | 0.03B | 0.03B | 0.04B | 0.04B | 0.04B | 0.04B |
| Cash flow | ||||||
| Cash from operations | $45.4M | $40.1M | $46.4M | $73.2M | $31.8M | $63.7M |
| Capital expenditure | $4.7M | $2.8M | $4.5M | $6.7M | $5.7M | $6.9M |
| Free cash flow | $40.7M | $37.3M | $41.9M | $66.5M | $26.1M | $56.8M |
| Depreciation and amortization | $14.7M | $13.7M | $15.7M | $15.7M | $16.4M | $18.6M |
| Stock-based compensation | — | $0.4M | $31.9M | $9.4M | $8.4M | $12.2M |
| Acquisitions | — | — | $55.5M | — | $142M | $89.6M |
| Dividends paid | — | $12.8M | $11.5M | $12.0M | $13.9M | $15.4M |
| Dividends and buybacks | — | $12.8M | $11.5M | $12.0M | $13.9M | $15.4M |
| Balance sheet | ||||||
| Cash and short-term investments | $2.9M | $33.9M | $45.3M | $87.7M | $125M | $123M |
| Total debt | $216M | $173M | $152M | $142M | $223M | $324M |
| Finance lease liabilities | — | — | — | — | — | $2.8M |
| Deposits | $3.1M | $7.6M | $10.1M | $9.8M | $10.0M | $32.5M |
| Current assets | $117M | $160M | $197M | $246M | $328M | $366M |
| Current liabilities | $62.5M | $74.6M | $78.9M | $95.2M | $94.1M | $104M |
| Inventory | $60.9M | $64.0M | $70.3M | $81.0M | $82.4M | $100M |
| Property and equipment, net | $35.4M | $33.1M | $45.3M | $44.6M | $45.2M | $78.8M |
| Goodwill | $66.3M | $66.3M | $81.6M | $81.7M | $148M | $181M |
| Intangible assets | $51.0M | $42.4M | $50.7M | $43.5M | $108M | $115M |
| Total assets | $283M | $312M | $392M | $431M | $653M | $770M |
| Total liabilities | $274M | $223M | $226M | $234M | $341M | $452M |
| Shareholders' equity | $8.9M | $88.6M | $166M | $197M | $312M | $318M |
| Margins | ||||||
| Gross margin | 37.8% | 39.9% | 38.4% | 41.6% | 41.1% | 42.5% |
| Operating margin | 12.3% | 12.1% | 3.7% | 11.7% | 11.8% | 11.0% |
| EBITDA margin | 15.9% | 15.3% | 7.1% | 15.0% | 14.7% | 14.1% |
| Net margin | 9.5% | 3.0% | 1.3% | 8.0% | 6.4% | 7.2% |
| FCF margin | 10.1% | 8.7% | 9.2% | 13.8% | 4.6% | 9.3% |
| Returns | ||||||
| Return on capital | 22.4% | 15.0% | 4.0% | 16.4% | 10.9% | 9.2% |
| Return on capital employed | 22.6% | 21.8% | 5.3% | 16.8% | 12.0% | 10.1% |
| Return on equity | 434.4% | 26.0% | 4.6% | 21.3% | 14.2% | 14.0% |
| Return on assets | 13.6% | 4.3% | 1.7% | 9.4% | 6.7% | 6.2% |
| Return on tangible equity | — | — | 17.3% | 53.7% | 64.7% | 206.1% |
| Growth | ||||||
| Revenue growth | — | 5.6% | 7.1% | 5.4% | 17.6% | 7.5% |
| Net income growth | — | −67.1% | −54.0% | 563.9% | −6.5% | 22.2% |
| EPS growth | — | −68.6% | −63.6% | 537.5% | −11.8% | 13.3% |
| FCF growth | — | −8.5% | 12.5% | 58.6% | −60.7% | 117.7% |
| Share count change | — | 4.1% | 26.3% | 5.0% | 6.4% | 7.7% |
| Financial health | ||||||
| Net debt / EBITDA | 3.3x | 2.1x | 3.3x | 0.8x | 1.2x | 2.4x |
| Debt / equity | 24.4x | 2.0x | 0.9x | 0.7x | 0.7x | 1.0x |
| Interest coverage | 2.0x | 3.1x | 2.7x | 12.5x | 8.5x | — |
| Current ratio | 1.9x | 2.1x | 2.5x | 2.6x | 3.5x | 3.5x |
| Quick ratio | 0.9x | 1.3x | 1.6x | 1.7x | 2.6x | 2.5x |
| Capital allocation | ||||||
| Capex / revenue | 1.2% | 0.7% | 1.0% | 1.4% | 1.0% | 1.1% |
| Stock comp / revenue | — | 0.1% | 7.0% | 1.9% | 1.5% | 2.0% |
| Payouts / FCF | — | 34.2% | 27.5% | 18.1% | 53.4% | 27.2% |
| Quality scores | ||||||
| Piotroski F-score | — | 6.0 | 5.0 | 7.0 | 3.0 | 6.0 |
| Altman Z'' | 2.1 | 2.9 | 2.7 | 3.9 | 4.0 | 3.7 |
| Accruals ratio | −2.5% | −9.2% | −11.5% | −8.4% | 0.8% | −2.8% |
Source: SEC EDGAR XBRL filings (CIK 0001860543). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.
